OpenLB
Open Library of Bioscience
Advanced Search
Der Pathologe
Jul, 2016;37 (4): 337-51.

[Grading of gynecological tumors : Current aspects].

L-C Horn, D Mayr, C E Brambs, J Einenkel, I Sändig, K Schierle
Author Information
  1. L-C Horn: Institut für Pathologie, Abteilung Mamma-, Gynäko- & Perinatalpathologie, Universitätsklinikum Leipzig AöR, Liebigstraße 26, 04103, Leipzig, Deutschland. hornl@medizin.uni-leipzig.de.
  2. D Mayr: Pathologisches Institut, Ludwig-Maximilins-Universität, München, Deutschland.
  3. C E Brambs: Frauenklinik des Klinikums rechts der Isar, Technischen Universität München, München, Deutschland.
  4. J Einenkel: Universitätsfrauenklinik Leipzig (Triersches Institut) im Zentrum für Frauen- und Kindermedizin, Universitätsklinikum Leipzig AöR, Leipzig, Deutschland.
  5. I Sändig: Institut für Pathologie, Abteilung Mamma-, Gynäko- & Perinatalpathologie, Universitätsklinikum Leipzig AöR, Liebigstraße 26, 04103, Leipzig, Deutschland.
  6. K Schierle: Institut für Pathologie, Abteilung Mamma-, Gynäko- & Perinatalpathologie, Universitätsklinikum Leipzig AöR, Liebigstraße 26, 04103, Leipzig, Deutschland.
PMID: 27379622 DOI: 10.1007/s00292-016-0183-7

Abstract

Histopathological assessment of the tumor grade and cell type is central to the management and prognosis of various gynecological malignancies. Conventional grading systems for squamous carcinomas and adenocarcinomas of the vulva, vagina and cervix are poorly defined. For endometrioid tumors of the female genital tract as well as for mucinous endometrial, ovarian and seromucinous ovarian carcinomas, the 3‑tiered FIGO grading system is recommended. For uterine neuroendocrine tumors the grading system of the gastrointestinal counterparts has been adopted. Uterine leiomyosarcomas are not graded. Endometrial stromal sarcomas are divided into low and high grades, based on cellular morphology, immunohistochemical and molecular findings. A chemotherapy response score was established for chemotherapeutically treated high-grade serous pelvic cancer. For non-epithelial ovarian malignancies, only Sertoli-Leydig cell tumors and immature teratomas are graded. At this time molecular profiling has no impact on the grading of tumors of the female genital tract.

Keywords

Endometrial cancer Molecular pathology Neuroendocrine malignancies Ovarian cancer Sertoli Leydig cell tumor

References

Pathology. 2011 Aug;43(5):420-32 [PMID: 21716157]
Gynecol Oncol. 1999 Jul;74(1):3-6 [PMID: 10385544]
Am J Surg Pathol. 2015 Jan;39(1):93-100 [PMID: 25188867]
Am J Surg Pathol. 1985 Aug;9(8):543-69 [PMID: 3911780]
Gynecol Oncol. 2001 Oct;83(1):89-94 [PMID: 11585418]
Gynecol Oncol. 1999 Aug;74(2):245-51 [PMID: 10419739]
Gynecol Oncol. 2014 Feb;132(2):334-42 [PMID: 24368280]
Int J Gynecol Pathol. 2004 Apr;23(2):110-8 [PMID: 15084838]
Indian J Pathol Microbiol. 2011 Oct-Dec;54(4):730-5 [PMID: 22234099]
Am J Surg Pathol. 2007 Nov;31(11):1653-61 [PMID: 18059221]
Int J Gynecol Pathol. 1987;6(3):203-12 [PMID: 3429105]
Gynecol Oncol. 2014 Feb;132(2):343-50 [PMID: 24321399]
Gynecol Oncol. 2006 Dec;103(3):906-11 [PMID: 16876852]
J Obstet Gynaecol Res. 2013 Jan;39(1):305-10 [PMID: 22691037]
Semin Diagn Pathol. 2010 Nov;27(4):274-86 [PMID: 21309261]
Pathologe. 2015 Nov;36(6):585-93 [PMID: 26483249]
Surg Pathol Clin. 2011 Mar;4(1):461-78 [PMID: 26837301]
J Clin Oncol. 2015 Aug 1;33(22):2457-63 [PMID: 26124480]
Geburtshilfe Frauenheilkd. 2015 Oct;75(10):1028-1042 [PMID: 26640293]
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S73-7 [PMID: 25341584]
Am J Surg Pathol. 2016 May;40(5):577-86 [PMID: 26945341]
Mod Pathol. 2012 Apr;25(4):625-36 [PMID: 22193042]
Am J Surg Pathol. 2010 Dec;34(12 ):1842-8 [PMID: 21107090]
Histopathology. 2014 Aug;65(2):149-54 [PMID: 24660659]
Gynecol Oncol. 2014 Mar;132(3):649-53 [PMID: 24462804]
Arch Pathol Lab Med. 2008 Nov;132(11):1753-60 [PMID: 18976011]
Int J Gynecol Pathol. 1994 Jan;13(1):62-72 [PMID: 8112957]
Int J Gynecol Pathol. 1994 Apr;13(2):99-108 [PMID: 8005742]
Ann Diagn Pathol. 2015 Feb;19(1):29-32 [PMID: 25596159]
Int J Gynecol Pathol. 2016 Mar;35(2):147-52 [PMID: 26535983]
Anticancer Res. 2016 Mar;36(3):1003-9 [PMID: 26976990]
Eur J Cancer. 2013 Dec;49(18):3839-49 [PMID: 24012099]
Arch Pathol Lab Med. 2006 Oct;130(10):1448-53 [PMID: 17090186]
Histopathology. 2007 May;50(6):773-9 [PMID: 17493241]
Ann Oncol. 2016 Jan;27(1):16-41 [PMID: 26634381]
Semin Diagn Pathol. 2013 Aug;30(3):224-33 [PMID: 24144291]
Int J Gynecol Pathol. 2004 Jul;23(3):200-5 [PMID: 15213595]
Am J Surg Pathol. 2007 Apr;31(4):592-7 [PMID: 17414107]
Int J Gynecol Pathol. 1993 Apr;12(2):141-7 [PMID: 8463038]
Int J Gynecol Pathol. 2013 Nov;32(6):592-601 [PMID: 24071876]
Pathologe. 2009 Jul;30(4):292-301 [PMID: 19495763]
Discov Med. 2014 Sep;18(98):133-40 [PMID: 25227754]
Int J Gynecol Pathol. 2003 Jan;22(1):71-4 [PMID: 12496701]
Gynecol Oncol. 2015 Feb;136(2):373-83 [PMID: 25481800]
Strahlenther Onkol. 2013 May;189(5):394-400 [PMID: 23553046]
Pathologe. 2014 Jul;35(4):322-6 [PMID: 24899496]
Histopathology. 2008 Aug;53(2):127-38 [PMID: 18298580]
Am J Surg Pathol. 2015 Mar;39(3):287-93 [PMID: 25581732]
Gynecol Oncol. 2014 Aug;134(2):385-92 [PMID: 24905773]
Pathologe. 2014 Sep;35(5):497-503 [PMID: 25069848]
Int J Gynecol Pathol. 2016 Jan;35(1):56-65 [PMID: 26166721]
Am J Surg Pathol. 2007 Aug;31(8):1168-74 [PMID: 17667538]
Gynecol Oncol. 2014 Jul;134(1):15-9 [PMID: 24844595]
Mod Pathol. 2010 Jun;23(6):781-9 [PMID: 20305618]
Int J Gynecol Pathol. 2005 Jan;24(1):4-25 [PMID: 15626914]
Int J Gynecol Cancer. 2004 Sep-Oct;14(5):741-50 [PMID: 15361180]
Am J Surg Pathol. 2015 May;39(5):667-72 [PMID: 25724003]
Int J Gynecol Pathol. 2013 Jan;32(1):45-65 [PMID: 23202790]
Int J Gynecol Pathol. 2006 Jan;25(1):52-8 [PMID: 16306785]
Lancet Oncol. 2014 Jul;15(8):852-61 [PMID: 24882434]
Ann Diagn Pathol. 2006 Jun;10(3):140-3 [PMID: 16730307]
Int J Gynecol Pathol. 2010 May;29(3):203-11 [PMID: 20407318]
Crit Rev Oncol Hematol. 2015 Apr;94(1):98-104 [PMID: 25468677]
Cancer. 1998 Mar 1;82(5):893-901 [PMID: 9486579]
Eur J Gynaecol Oncol. 2008;29(3):260-3 [PMID: 18592791]
Cancer. 2004 Feb 15;100(4):764-72 [PMID: 14770433]
Gynecol Oncol. 2015 Feb;136(2):205-11 [PMID: 25546113]
Nature. 2011 Jun 29;474(7353):609-15 [PMID: 21720365]
J Clin Pathol. 2010 May;63(5):410-5 [PMID: 20418232]
Int J Gynecol Pathol. 2004 Apr;23(2):97-9 [PMID: 15084836]
Gynecol Oncol. 2016 Apr;141(1):148-54 [PMID: 26854651]
Am J Surg Pathol. 2008 Mar;32(3):383-9 [PMID: 18300813]
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S78-82 [PMID: 25341585]
Mod Pathol. 2015 Apr;28(4):505-14 [PMID: 25394778]
Gynecol Endocrinol. 2013 May;29(5):412-7 [PMID: 23379421]
Pharmacol Ther. 2015 May;149:139-49 [PMID: 25550229]
Am J Surg Pathol. 1984 Jun;8(6):405-18 [PMID: 6731664]
Arch Gynecol Obstet. 2014 Nov;290(5):839-42 [PMID: 25082067]
Anticancer Res. 2010 Jun;30(6):2311-7 [PMID: 20651385]
Cancer. 1959 Mar-Apr;12(2):384-8 [PMID: 13638958]
Annu Rev Pathol. 2014;9:27-45 [PMID: 23937438]
Int J Clin Exp Pathol. 2014 Jun 15;7(7):4222-30 [PMID: 25120802]
Cancer. 1992 Jan 1;69(1):208-12 [PMID: 1309304]
Int J Clin Oncol. 2015 Aug;20(4):782-9 [PMID: 25380693]
Am J Pathol. 2016 Apr;186(4):733-47 [PMID: 27012190]
Am J Surg Pathol. 2005 Mar;29(3):295-304 [PMID: 15725797]
Am J Surg Pathol. 2015 Jul;39(7):983-92 [PMID: 25723110]
Int J Gynecol Pathol. 2012 Nov;31(6):499-506 [PMID: 23018212]
Klin Padiatr. 2006 Nov-Dec;218(6):309-14 [PMID: 17080332]
Int J Gynecol Pathol. 1994 Oct;13(4):283-9 [PMID: 7814189]
Am J Surg Pathol. 2002 Dec;26(12):1529-41 [PMID: 12459620]
Eur J Obstet Gynecol Reprod Biol. 2012 Jul;163(1):76-80 [PMID: 22480414]
Am J Surg Pathol. 2000 Sep;24(9):1201-8 [PMID: 10976693]
Clin Cancer Res. 2008 Aug 15;14(16):5198-208 [PMID: 18698038]
Nature. 2013 May 2;497(7447):67-73 [PMID: 23636398]
Gynecol Oncol. 2014 Aug;134(2):410-8 [PMID: 24875120]
Pathologe. 2014 Jul;35(4):336-47 [PMID: 24859239]
Gynecol Oncol. 2014 Mar;132(3):643-8 [PMID: 24418199]
Cancer. 2012 Jun 15;118(12):3087-94 [PMID: 22072418]
Int J Gynecol Pathol. 2011 Mar;30(2):129-38 [PMID: 21293288]
Crit Rev Oncol Hematol. 2013 May;86(2):161-75 [PMID: 23137764]
Cancer. 1976 May;37(5):2359-72 [PMID: 1260722]
Cancer. 1995 Jan 1;75(1):81-6 [PMID: 7804981]
Mod Pathol. 2015 Aug;28(8):1101-22 [PMID: 26089092]
Am J Obstet Gynecol. 2011 Nov;205(5):480.e1-8 [PMID: 21861962]
Int J Gynecol Pathol. 2007 Oct;26(4):447-56 [PMID: 17885497]
Int J Gynecol Pathol. 2008 Apr;27(2):175-81 [PMID: 18317226]
Gynecol Oncol. 2015 Nov;139(2):236-41 [PMID: 26404183]
Am J Surg Pathol. 2004 Apr;28(4):496-504 [PMID: 15087669]
Gynecol Oncol. 1990 Sep;38(3):352-7 [PMID: 2227547]
Adv Anat Pathol. 2012 Jan;19(1):1-10 [PMID: 22156830]
Int J Gynecol Pathol. 2016 Jan;35(1):78-81 [PMID: 26598986]
Gynecol Oncol. 2012 Aug;126(2):279-85 [PMID: 22555104]
Hum Pathol. 2009 Sep;40(9):1213-23 [PMID: 19552940]
Lancet. 2012 Apr 7;379(9823):1352-60 [PMID: 22444602]
Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [PMID: 10638449]
Obstet Gynecol. 2009 May;113(5):1038-45 [PMID: 19384118]

MeSH Term

Adenocarcinoma
Carcinoma, Squamous Cell
Endometrial Neoplasms
Female
Genital Neoplasms, Female
Genitalia, Female
Humans
Neoplasm Grading
Neoplasm Staging
Neuroendocrine Tumors
Ovarian Neoplasms
Prognosis
Sertoli-Leydig Cell Tumor
Uterine Cervical Neoplasms
Vaginal Neoplasms
Vulvar Neoplasms
Journal Article Review

Word Cloud

Similar Articles

Cited By